Vanguard Group Inc. Has $85.74 Million Stock Holdings in Arvinas, Inc. $ARVN

Vanguard Group Inc. cut its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 15.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 7,229,603 shares of the company’s stock after selling 1,331,629 shares during the quarter. Vanguard Group Inc. owned about 0.11% of Arvinas worth $85,743,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in Arvinas during the 1st quarter worth approximately $727,000. Jacobs Levy Equity Management Inc. bought a new position in Arvinas during the 1st quarter worth approximately $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after purchasing an additional 2,122 shares during the last quarter. Millennium Management LLC raised its holdings in Arvinas by 208.4% during the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after purchasing an additional 885,483 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Arvinas by 108.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock worth $6,339,000 after purchasing an additional 469,394 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on ARVN. Wall Street Zen lowered shares of Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Wedbush raised their price target on shares of Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Arvinas in a report on Friday, April 10th. Citigroup raised their price target on shares of Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Finally, BTIG Research raised their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $15.14.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Arvinas and Pfizer struck a global licensing agreement with Rigel Pharmaceuticals for exclusive rights to VEPPANU, bringing in $85 million upfront and transition payments, plus up to $320 million in additional milestones and royalties. That deal helps validate the asset and provides non-dilutive funding. Article Title
• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a buy rating, signaling improved analyst confidence after the latest news flow. Article Title
• Neutral Sentiment: Arvinas reported first-quarter results showing a smaller-than-expected loss per share, though revenue missed estimates. The report also highlighted pipeline progress, including FDA approval for VEPPANU, updated clinical data for ARV-102, and initiation of dosing for ARV-027. Article Title
• Neutral Sentiment: The CEO, CFO, CAO, and another insider sold shares, but the company said the transactions were tied to tax withholding obligations from vesting equity awards, which makes them less concerning than open-market selling. Article Title

Arvinas Stock Up 3.1%

NASDAQ:ARVN opened at $9.87 on Thursday. The company has a fifty day moving average of $11.14 and a 200-day moving average of $11.69. The firm has a market capitalization of $636.81 million, a P/E ratio of -2.97 and a beta of 1.79. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $14.51.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.05. The company had revenue of $15.60 million during the quarter, compared to analyst estimates of $16.61 million. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. Arvinas’s revenue for the quarter was down 91.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 EPS. On average, analysts anticipate that Arvinas, Inc. will post -3.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Andrew Saik sold 11,139 shares of Arvinas stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the sale, the chief financial officer owned 193,128 shares in the company, valued at $1,919,692.32. The trade was a 5.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Noah Berkowitz sold 11,108 shares of Arvinas stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $110,413.52. Following the completion of the sale, the insider owned 191,395 shares of the company’s stock, valued at $1,902,466.30. This represents a 5.49% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 97,687 shares of company stock worth $1,138,643 over the last ninety days. 7.30% of the stock is owned by company insiders.

Arvinas Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.